Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Verona Pharma reports $36.6 million in Ohtuvayre sales for Q4 2024, with ongoing Phase 2 trials advancing. Verona Pharma plc announced its financial results for the fourth quarter and full year of ...

and now Verona has revealed the drug made approximately $36 million in the final three months of 2024, off more than 16,000 prescriptions. Chief executive David Zaccardelli said Ohtuvayre was off ...

“2024 was another transformational year for Verona Pharma with the US approval and launch of Ohtuvayre (ensifentrine), the first novel inhaled therapy available for the maintenance treatment of ...

Ohtuvayre (ensifentrine ... talk with your doctor or pharmacist. A program called Verona Pathway Plus may also be available. »Learn more about saving on your prescriptions.

Verona Pharma (VRNA ... Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and ...

“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD ...

Truist analyst Joon Lee raised the firm’s price target on Verona Pharma (VRNA ... metrics shared imply continued launch momentum for Ohtuvayre, with 600 new prescriber adds per month, the ...

"2024 was another transformational year for Verona Pharma with the US approval and launch of Ohtuvayre (ensifentrine), the first novel inhaled therapy available for the maintenance treatment of ...